8 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasmRecruitingPhase 22026-09-18NCT07450859
Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational ProductAdvanced Solid TumorsNot yet recruitingPhase 22026-07-02NCT07681674
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 22026-05-27NCT06225596
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung CancerNeoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-04-15NCT06933329
Study of Zelenectide Pevedotin in Participants With Advanced Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-04-15NCT06840483
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 ExpressionAdvanced Solid TumorActive, not recruitingPhase 1 / Phase 22026-01-15NCT05163041
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, head and neck cancer, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, stomach disorder, triple-negative breast carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 1 / Phase 22025-11-17NCT04180371
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, kidney disorder, kidney failure, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, skin disorder, triple-negative breast carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 1 / Phase 22025-11-14NCT04561362